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OBJECTIVES: The objective of this early postlaunch analysis
was to examine medication persistence among women °Y´45
years and newly prescribed monthly or weekly bisphosphonate
(BP) therapy at 9 months. METHODS: The i3 Innovus admin-
istrative claims database was used to retrospectively identify
female patients who ﬁlled a new prescription for a weekly BP
(risedronate or alendronate) or monthly ibandronate starting in
April 2005. Medication persistence was deﬁned as having no
reﬁll gaps exceeding grace periods of 30 (weekly BPs) and 45
days (monthly BPs). Cox proportional hazard analysis was used
to control for the effects of potential confounding factors includ-
ing age, co-pay, and co-morbidities. RESULTS: This analysis
included 967 women prescribed monthly ibandronate and 8662
women prescribed weekly BPs. At 9-months, the median number
of days until discontinuation was 236 days for monthly and 141
days for weekly (p < 0.0001). Signiﬁcantly more patients receiv-
ing monthly ibandronate were persistent compared to patients
receiving weekly BPs (48% vs 35%, P < 0.0001). After adjust-
ing for potential confounding factors, monthly users overall were
38.0% more likely to persist with therapy versus weekly users
(hazard ratio = 0.620, 95% CI 0.563–0.683, P < 0.0001). CON-
CLUSION: The 9-month results of this analysis indicate that
more women on monthly therapy are persistent than women on
weekly bisphosphonates. This early ﬁnding suggests enhanced
long-term persistence with ibandronate monthly therapy, with
the potential for improved clinical outcomes. Follow-up of this
cohort is ongoing.
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OBJECTIVES: Data from health care databases are used to
determine patient persistence with bisphosphonates in a real-
world setting. The observational nature of retrospective database
studies removes a source of potential inﬂuence on patient behav-
ior. The objective of this analysis is to evaluate 9-month persis-
tence among patients receiving monthly ibandronate versus
weekly bisphosphonates. METHODS: De-identiﬁed patient data
were collected from the HealthCore managed care claims data-
base, which represents over 17.5 million covered lives. Eligible
women were °Y´45 years and ﬁlled a new prescription for
monthly ibandronate or weekly alendronate or risedronate start-
ing April 1, 2005. Persistence was evaluated based on a gap in
coverage of 30 days for weekly bisphosphonates; a 45-day gap
was analyzed for monthly ibandronate due to its 3-week dosing
window. Cox proportional hazard models were used to analyze
persistence and controlled for potential confounders such as age,
patient co-pay, and comorbidities. RESULTS: A total of 4548
women were included (213 receiving monthly ibandronate and
4335 receiving weekly therapy). The median number of days
until discontinuation for monthly was 145 days and for weekly
was 115 days (p = 0.0032). At 9 months, signiﬁcantly more
patients receiving monthly ibandronate (41%) were persistent
compared to patients receiving weekly BPs (33%) (P = 0.003).
After adjusting for age, co-pay, comorbidities, and prescriptions
with greater than a 30-day supply, monthly users were 31% less
likely to discontinue therapy compared with weekly users at 9
months (P < 0.0001). CONCLUSION: Persistence during the
initial 9 months after launch of ibandronate was higher for iban-
dronate monthly BP therapy than weekly BP therapy. Longer
follow-up of this cohort is ongoing.
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OBJECTIVES: For survivors of traumatic injury, critical care ser-
vices are often required, followed by long-term recovery as
patients overcome or adapt to the effects of their injury on phys-
ical function (Holtslag, 2006). Recently, increased attention has
been focused on the use of patient reported outcome (PRO)
assessments to evaluate functional outcomes in this population.
In order to appraise current validation evidence for the use of a
simple-to-administer PRO (Physical Function (PF) Scale of the
Medical Outcomes Study Short-Form (SF-36) health survey), a
literature review was completed. METHODS: Comprehensive
literature review (including a review of articles identiﬁed from
previous work with trauma patient populations and with the SF-
36 as well as a comprehensive search of PUBMED & EMBASE,
2000–2006 for articles that used PRO measures to assess recov-
ery in trauma patients); 92 articles were reviewed. RESULTS:
Ten studies presented psychometric data for the SF-36 in trauma
patients (number of trauma patients included in these studies
ranged from 64–1197). PF Scale properties were as follows:
Internal consistency reliability: Alpha = 0.93 (multiple trauma
patients; Statz, 2002). Discriminant validity: The PF Scale 
discriminated between patients with different injury types
(Michaels, 2001). Trauma patients had signiﬁcantly lower PF
scores (p < 0.001) than control patients with no disability
(Findler, 2001) and US norms at various time points (up to 27
months) post-trauma (Brennenman, 1995; Holtslag, 2006;
Hoogendoorn, 2001). Concurrent validity: PF scores were sig-
niﬁcantly related to those on the Sickness Impact Proﬁle (Holt-
